{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:38:48Z","timestamp":1794573528457,"version":"4.9.1"},"reference-count":10,"publisher":"SLACK, Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>To describe the Port Delivery System with ranibizumab refill-exchange procedure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Procedure based on the clinical trial program in patients with retinal diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>The refill-exchange procedure is performed under topical anesthesia and strict aseptic conditions. Supplemental task lighting and magnification are recommended throughout the procedure. Ranibizumab is aseptically transferred from the vial with the filter needle and air is removed from the syringe. The filter needle is then replaced with the refill needle; any remaining air is removed from the syringe and the plunger is advanced to the 0.1-mL mark. Targeting the implant septum center, the refill needle is inserted perpendicularly to the globe until the soft stop contacts the conjunctiva (perpendicular orientation and conjunctival contact are maintained throughout the procedure); a cotton-tipped applicator is recommended for globe stabilization. The entire syringe contents are slowly injected over 5\u201310 seconds while existing solution fills the fluid collection reservoir. Once completed, the needle is carefully withdrawn while maintaining perpendicularity. The procedure can be successfully performed in rare, specific cases, including subconjunctival thickening or fibrous capsule formation, fluid-filled bleb formation, and corneal patch grafts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>The procedure is straightforward but distinct from intravitreal injections and requires adherence to standardized techniques. With appropriate preparation, the procedure can be performed in specific cases.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        [\n                        <jats:italic toggle=\"yes\">Ophthalmic Surg Lasers Imaging Retina.<\/jats:italic>\n                        2022;53:257\u2013265.]\n                      <\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3928\/23258160-20220412-01","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T10:10:15Z","timestamp":1652695815000},"page":"257-265","source":"Crossref","is-referenced-by-count":15,"title":["Refill-Exchange Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Trial Experience"],"prefix":"10.3928","volume":"53","author":[{"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Barteselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun K.","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia R.","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia F.","family":"Callaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_2_2_2","volume-title":"SUSVIMOTM (ranibizumab injection) Instructions for Use","year":"2021","unstructured":"SUSVIMOTM (ranibizumab injection) Instructions for Use. Genentech, Inc., a member of the Roche Group, South San Francisco, CA. October 2021."},{"key":"e_1_3_2_3_2","volume-title":"SUSVIMOTM (ranibizumab injection) Prescribing Information","year":"2022","unstructured":"SUSVIMOTM (ranibizumab injection) Prescribing Information. Genentech, Inc., a member of the Roche Group, South San Francisco, CA. April 2022."},{"key":"e_1_3_2_4_2","volume-title":"Presented at: The Association for Research in Vision and Ophthalmology Annual Meeting","author":"Stewart JM","unstructured":"Stewart JM, Tam T, Horvath J. The Port Delivery System with ranibizumab (PDS)\u2014a new paradigm for long-acting retinal drug delivery. Presented at: The Association for Research in Vision and Ophthalmology Annual Meeting; San Francisco, CA; May 2\u20136, 2021."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20220408-01"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.09.016"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.036"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.11.004"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.3.338"},{"key":"e_1_3_2_10_2","article-title":"Management of key ocular adverse events in patients implanted with the Port Delivery System with ranibizumab","author":"Awh CC","unstructured":"Awh CC, Barteselli G, Makadia S. Management of key ocular adverse events in patients implanted with the Port Delivery System with ranibizumab. Submitted to Ophthalmol Retina.","journal-title":"Submitted to Ophthalmol Retina"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20220415-03"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:20:43Z","timestamp":1783527643000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20220412-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,1]]}},"alternative-id":["10.3928\/23258160-20220412-01"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20220412-01","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}